Hansa Raises More Cash For Pipeline With Genovis Stake Sale
Executive Summary
The Swedish group has sold its stake in Genovis, raising about $9.6m that will help advance lead candidate imlifidase.
You may also be interested in...
Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.